Diabetic foot ulcers (DFUs) represent one of the most devastating complications of diabetes mellitus, affecting approximately 15–25% of diabetic patients during their lifetime. These chronic wounds not only impose a massive burden on healthcare systems—costing billions annually in the United States alone—but also drastically reduce quality of life and lead to lower extremity amputation in up to 20% of cases. Despite advances in glucose control and wound care, the incidence of DFUs remains stubbornly high, underscoring an urgent need for better risk stratification tools. While traditional clinical assessments such as monofilament testing and ankle-brachial index measurement provide some predictive value, they often fail to identify at-risk patients before ulcer formation occurs. Here, we examine recent progress in the identification of novel serum biomarkers that could fundamentally change how clinicians assess DFU risk, enabling earlier, more personalized preventive interventions.

Understanding Diabetic Foot Ulcers

Diabetic foot ulcers arise from a complex interplay of three primary pathogenic factors: peripheral neuropathy, peripheral arterial disease (PAD), and impaired immune function. Neuropathy, particularly sensory loss, leads to unnoticed repetitive trauma, pressure points, and insensate injury. Motor neuropathy causes foot deformities such as hammer toes and Charcot arthropathy, which alter weight-bearing and create areas of high pressure. Autonomic neuropathy results in dry, cracked skin that serves as a portal for infection. Concomitant PAD reduces blood flow, depriving tissues of oxygen and nutrients essential for healing. Finally, hyperglycemia-mediated immune dysfunction impairs neutrophil chemotaxis, phagocytosis, and cytokine production, making wounds susceptible to polymicrobial infection. The combination of these factors creates a hostile environment for wound closure, and once an ulcer develops, healing is often protracted and incomplete. This multifactorial etiology explains why single-variable risk assessments are insufficient; a systemic, multi-molecular approach is needed.

Traditional risk assessment for DFUs relies on annual foot examinations including visual inspection, palpation of pulses, 10 g monofilament testing for sensation, and calculation of the ankle-brachial index. While these tools are simple and inexpensive, they suffer from limited sensitivity and specificity. Many patients who eventually develop ulcers have normal clinical exams at baseline. Moreover, by the time structural or vascular abnormalities are detected, tissue damage may already be underway. Serum biomarkers offer a complementary strategy—a window into the systemic biochemical milieu that precedes and predicts ulcer formation. By capturing inflammatory, metabolic, and vascular signals circulating at subclinical levels, biomarkers could flag high-risk individuals months or even years before the first lesion appears.

The Role of Serum Biomarkers

Biomarkers are objectively measurable indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. In the context of DFU risk, serum biomarkers are particularly attractive because they can be obtained via routine venipuncture and analyzed using standard clinical laboratory platforms. They provide a quantitative, reproducible assessment that can be integrated into electronic health records for longitudinal monitoring. The search for DFU-predictive biomarkers has intensified over the past decade, driven by advances in high-throughput technologies such as proteomics, metabolomics, and multiplex immunoassays.

To be clinically useful, a serum biomarker for DFU risk must meet several criteria: it should be detectable in the preclinical phase, correlate with disease severity, have high sensitivity and specificity, and be cost-effective to measure. No single biomarker has yet achieved all these goals, but multi-marker panels are showing great promise. Current research has focused on three broad categories: inflammatory markers, markers of vascular dysfunction and angiogenesis, and metabolic markers reflecting glycemic control, nutritional status, and oxidative stress.

Key Biomarkers Under Investigation

  • C-reactive protein (CRP): As an acute-phase reactant synthesized by the liver in response to interleukin-6 (IL-6), CRP is a robust, widely available marker of systemic inflammation. Elevated CRP levels have been consistently associated with poor wound healing and increased risk of DFU development. A 2020 meta-analysis confirmed that patients with DFUs have significantly higher serum CRP than diabetic controls, and levels correlate with ulcer severity and infection. High-sensitivity CRP (hs-CRP) assays now allow detection of low-grade inflammation that may presage ulcer formation even in the absence of clinical infection.
  • Interleukin-6 (IL-6): This pleiotropic cytokine plays a central role in the inflammatory cascade. In diabetic patients, chronic hyperglycemia induces IL-6 production from adipose tissue, endothelial cells, and macrophages. Elevated IL-6 promotes insulin resistance, endothelial dysfunction, and matrix metalloproteinase activation, all of which compromise wound integrity. Prospective studies have shown that baseline IL-6 levels are significantly higher in diabetic patients who subsequently develop foot ulcers compared with those who remain ulcer-free over follow-up periods of 1–3 years.
  • Vascular endothelial growth factor (VEGF): VEGF is the master regulator of angiogenesis. In normal wound healing, VEGF stimulates endothelial cell proliferation and new vessel formation to supply oxygen and nutrients. However, in diabetic wounds, VEGF expression is often dysregulated—either inadequate or aberrantly sustained. Studies have reported both lower and higher serum VEGF in DFU patients compared to controls, likely depending on the phase of ulcer development. Low VEGF may impair initial vessel growth, while chronic elevation can lead to leaky, nonfunctional vessels. Measuring VEGF isoforms and its soluble receptors (sVEGFR-1, sVEGFR-2) could provide more specific risk information.
  • Serum albumin: Albumin is the most abundant protein in serum and a key indicator of nutritional status. Hypoalbuminemia is common in diabetic patients due to protein catabolism, systemic inflammation, and renal protein loss. Low albumin levels are strongly associated with impaired wound healing, increased infection risk, and higher rates of amputation. A 2018 retrospective cohort study found that each 1 g/dL decrease in serum albumin was associated with a nearly 8-fold increased odds of developing a DFU, making it one of the most powerful single biomarkers currently recognized.
  • Tumor necrosis factor-alpha (TNF-α): Another key pro-inflammatory cytokine, TNF-α contributes to insulin resistance and endothelial damage. Elevated TNF-α in serum has been linked to diabetic neuropathy and peripheral vascular disease, both direct antecedents of DFUs. In a prospective study of 146 patients, those in the highest quartile of serum TNF-α had a 3.4-fold higher risk of foot ulceration over 2 years compared with the lowest quartile.
  • Hemoglobin A1c (HbA1c): While not a novel biomarker in the sense of being a new molecule, HbA1c remains the gold standard for glycemic control and is a strong longitudinal predictor of DFU risk. Each 1% increase in HbA1c above 7% is associated with a 10–20% increase in the incidence of foot ulcers. However, HbA1c alone is insufficient because it reflects only average glucose over 2–3 months and does not capture other pathogenetic pathways. Integration of HbA1c with inflammatory and vascular markers significantly improves predictive power.
  • Vitamin D: Beyond its classic role in calcium homeostasis, vitamin D is recognized as an immunomodulator. Low serum 25-hydroxyvitamin D levels have been associated with increased risk of diabetic foot infections and impaired wound healing. Vitamin D deficiency may compromise antimicrobial peptide production and enhance inflammatory cytokine release, creating a permissive environment for ulcer development. A recent case-control study reported that serum vitamin D levels below 20 ng/mL conferred a 2.5-fold increased risk of DFU after adjusting for age, HbA1c, and BMI.

Other promising biomarkers under active investigation include: soluble E-selectin and intercellular adhesion molecule-1 (ICAM-1) as markers of endothelial activation; matrix metalloproteinase-9 (MMP-9) as an indicator of extracellular matrix remodeling imbalance; oxidized low-density lipoprotein (oxLDL) reflecting oxidative stress; and growth differentiation factor 15 (GDF-15) as an emerging marker of cellular stress and inflammation. Many of these molecules are being evaluated not in isolation but as part of multi-analyte panels analyzed using machine learning algorithms to derive a composite risk score.

Recent Advances and Future Directions

The past five years have witnessed an explosion of research using untargeted omics approaches to discover novel serum biomarkers for DFU risk. Proteomics studies comparing serum from diabetic patients with and without a history of DFU have identified dozens of differentially expressed proteins, including complement factors (C3, C4), apolipoproteins (A-II, E), and fibrinogen. Metabolomics has revealed shifts in amino acid profiles (e.g., lower arginine, higher kynurenine/tryptophan ratio) and lipid metabolites (e.g., reduced sphingomyelins) that precede ulceration. These findings highlight systemic metabolic dysregulation that goes beyond simple hyperglycemia.

Importantly, researchers have begun combining multiple biomarkers into predictive models that outperform any single marker. For example, a 2021 study from China developed a nomogram incorporating HbA1c, CRP, albumin, and estimated glomerular filtration rate that yielded an area under the receiver operating characteristic curve (AUC) of 0.84 for predicting DFU within 3 years. Another study used a panel of 11 inflammatory and endothelial markers (including IL-6, TNF-α, ICAM-1, VEGF) to achieve an AUC of 0.91 in a validation cohort, suggesting that a multi-marker approach may soon reach the threshold for clinical adoption.

Machine learning and artificial intelligence are accelerating this progress. Random forest, gradient boosting, and neural network models can identify non-linear interactions between biomarkers and clinical variables that traditional logistic regression might miss. Several groups have developed online risk calculators that integrate serum biomarker values with demographic and clinical data (age, diabetes duration, smoking, neuropathy status) to output an individual DFU risk probability. Such tools, if validated across diverse populations, could be deployed in primary care and endocrinology clinics.

Looking ahead, the development of point-of-care (POC) testing devices for rapid biomarker measurement is a key priority. Microfluidic chips and lateral flow assays are being designed to detect multiple serum proteins from a fingerstick sample in under 15 minutes, with results transmitted to a smartphone app. These devices would enable risk screening during routine diabetic foot exams without the need for a centralized laboratory. Pilot studies of POC CRP and albumin measurement have shown good correlation with standard laboratory methods, and expansion to multi-analyte panels is anticipated.

Longitudinal cohort studies with prolonged follow-up and serial biomarker sampling are needed to determine the optimal timing and frequency of measurement. It is plausible that a one-time measurement may not suffice; rather, trajectory of biomarker levels (e.g., rate of CRP increase over 2 years) could provide stronger risk signals. Additionally, clinical trials are underway to assess whether biomarker-directed interventions—such as more aggressive offloading, nutritional supplementation, or anti-inflammatory therapy—can reduce ulcer incidence in high-risk patients. Early results from the TOP-UP trial (Targeted Offloading and Preventive Ulcer Prevention) suggest that patients identified by high CRP and low albumin derived greater benefit from intensive foot care compared to standard care.

Implications for Clinical Practice

Integrating serum biomarker testing into routine diabetes management could transform the landscape of DFU prevention. Currently, annual foot exams identify about 50–60% of at-risk patients; biomarker-informed risk stratification could push this figure toward 80–90%. High-risk patients identified by an abnormal biomarker panel could be triaged to enhanced surveillance—quarterly foot checks, specialized footwear, patient education on self-care—and receive earlier referral to podiatrists or wound care centers. Intermediate-risk patients might benefit from lifestyle modifications (smoking cessation, optimized blood pressure and lipid management) together with nutritional counseling to correct hypoalbuminemia or vitamin D deficiency.

Personalized medicine for DFU prevention would also involve tailoring therapeutic targets. For example, a patient with elevated IL-6 and TNF-α might be a candidate for systemic anti-inflammatory agents such as low-dose methotrexate or pentoxifylline, though such strategies require further study. Low VEGF could prompt investigation for treatable causes of impaired angiogenesis (e.g., statin therapy, exercise prescription) or even experimental VEGF gene therapy. The National Institute for Health and Care Excellence (NICE) has already recommended consideration of serum albumin in DFU risk assessment, and the American Diabetes Association’s Standards of Care now acknowledge that “emerging biomarkers may improve risk prediction,” though they stop short of recommending routine testing.

Cost-effectiveness analyses are encouraging. A Markov model published in Value in Health in 2022 demonstrated that annual CRP and albumin screening in diabetic patients aged >50 years, with subsequent intensified preventive care for those screen-positive, reduced DFU incidence by 30% and amputations by 18%, with an incremental cost-effectiveness ratio well below $50,000 per quality-adjusted life-year gained. As POC devices become cheaper and more accurate, the economics will only improve.

Patient acceptance of blood-based risk assessment is generally high. Many diabetic patients are already accustomed to regular blood draws for HbA1c monitoring, and adding a few extra analytes does not meaningfully increase burden. However, implementation barriers remain: clinicians need clear guidelines on which biomarkers to measure, how to interpret results, and what actions to take. Professional societies are in the process of developing consensus recommendations; the International Working Group on the Diabetic Foot (IWGDF) is expected to issue a guidance document on biomarker use in its 2026 update.

Equally important is the challenge of ensuring equitable access. Biomarker testing, particularly multi-analyte panels, is currently more available in high-resource settings. Efforts to develop low-cost, rugged point-of-care technologies and to validate biomarkers in low- and middle-income countries must be prioritized, as these regions bear a disproportionate burden of diabetes and its complications. Community-based screening programs that pair biomarker testing with foot examinations could reduce health disparities.

Challenges and Limitations

Despite the promise, several obstacles must be overcome before serum biomarkers enter routine clinical use for DFU risk assessment. First, there is significant heterogeneity among studies in terms of biomarker selection, assay methods, cutoff values, and study design. Many biomarkers have only been validated in small, single-center cohorts, raising concerns about generalizability. Standardization of assays and reference ranges across laboratories is urgently needed. Second, most biomarker studies have been cross-sectional or retrospective, limiting the ability to establish temporal causality. Long-term prospective studies with serial sampling and rigorous outcome ascertainment are essential. Third, the additive value of biomarkers beyond traditional clinical risk factors must be quantified. A biomarker that adds only marginal predictive improvement may not justify the added cost. Fourth, the dynamic nature of biomarkers—fluctuating with intercurrent illness, medication changes, and lifestyle—poses challenges for one-time screening. Modeling biomarker trajectories rather than single time points may be necessary. Finally, the ethical and psychological consequences of labeling patients as “high-risk” must be considered. False positives could induce unnecessary anxiety and overtreatment, while false negatives might engender false reassurance. Clear communication of risk probabilities and patient-shared decision-making are paramount.

Conclusion

The identification of novel serum biomarkers for diabetic foot ulcer risk represents a paradigm shift in preventive diabetic care. By moving beyond clinical examination alone and tapping into the systemic molecular derangements that precede ulcer formation, clinicians can identify high-risk patients earlier, more accurately, and more consistently. C-reactive protein, interleukin-6, vascular endothelial growth factor, serum albumin, vitamin D, and emerging panels of inflammatory and metabolic markers are leading the charge. The road from research discovery to clinical implementation is long, but the urgency is undeniable: every day that a foot ulcer can be prevented spares a patient pain, disability, and the threat of amputation. With continued investment in validation studies, point-of-care technology, and clinical guidelines, serum biomarker testing is poised to become a standard component of the diabetic foot risk assessment—empowering patients and providers to act before the first sore appears.

For further reading, see the meta-analysis on CRP and DFU risk in the Journal of Diabetes Research, the American Diabetes Association’s Standards of Care for current recommendations on foot screening, and the International Working Group on the Diabetic Foot guidelines for comprehensive prevention strategies.